ResMed
ResMed is a global medical technology company that develops, manufactures, and sells cloud-connected devices and software for the diagnosis, treatment, and management of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. It serves sleep labs, hospitals, home medical equipment providers, and patients worldwide through a mix of device sales, consumables, and subscription-based digital health and SaaS solutions. The company also offers out-of-hospital care management platforms for providers and payers to monitor and manage chronic disease populations remotely.
- Electronic Health Records
- Patient Engagement & Telehealth
- Clinical Trial & Research Software
- Revenue
- $4.4B
- Employees
- 10,500
- Founded
- 1989
- Headquarters
- San Diego, United States of America
What 20 Arbolus experts think of ResMed
NPS scores skew high, with 72% in the promoter range (scores 8-10) and no visible detractors. Long-term use is widespread, with over 90% of respondents reporting implementation stages of more than one year. Strong renewal intent is present among high-spender influencers, while some uncertainty remains for users with moderate spend. Customer sentiment emphasizes ResMed's reliability, global presence, and strong brand—although minor technical gaps are referenced. Overall Customer Sentiment: Positive
Who reviewed ResMed
- C-Suite 55% (11)
- Director 10% (2)
- Manager 35% (7)
Employer names and spend open in the full report, along with the other 17 customers.
Everything 20 customers told us about ResMed.
Employer names, spend, renewal intent and every written answer behind the numbers on this page.
Sentiment
65 Net Promoter Score, from 20 scored reviews- Promoters 13
- Passives 7
- Detractors 0
Cumulative NPS by month
-1 over 6 months- Aug 10
- Dec 10
- Jan 9
- Aug 8
- Sep 9
- Oct 9
Net Promoter Score across 2 reviews, accumulated up to each month. Category median 41 across 2 companies.
Praised
- Ease of Use for Technicians
- Remote Monitoring Capabilities
- Global Brand and Ubiquity
- Precision AI-Assisted Diagnostics
Criticised
- Competitive AI Precision
- Regulatory Barriers to Automation
- Ease and Ergonomics of Competing Solutions
- Inability to Serve Particular Treatment Cases
What customers say
Renewal intent
Plan to renew 63%Plan to renew, by seniority
- 60% 5 answers
- 67% 3 answers
- 9.6/10 Average score from customers who will renew
- 8.3/10 Average score from undecided customers
Top alternatives
Most weighed by ResMed customersReport
For people who use ResMed
Do you use ResMed at work?
Share your software review and get matched to paid projects. Arbolus pays you every time a client reads your review.
- 20 customers of ResMed have already contributed
Takes a few minutes. Your identity stays anonymous.